These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19191252)

  • 1. Beneficiary price sensitivity in the Medicare prescription drug plan market.
    Frakt AB; Pizer SD
    Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attribute substitution in early enrollment decisions into Medicare prescription drug plans.
    Frakt AB; Pizer SD
    Health Econ; 2008 Apr; 17(4):513-21. PubMed ID: 17935198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost minimization of medicare part D prescription drug plan expenditures.
    Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
    Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting risk selection following major changes in Medicare.
    Pizer SD; Frakt AB; Feldman R
    Health Econ; 2008 Apr; 17(4):453-68. PubMed ID: 17557273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential opportunity cost of neglecting to annually reassess Medicare Part D standalone prescription drug plan offerings: the price of contentment?
    Walberg MP; Patel RA
    J Am Pharm Assoc (2003); 2009; 49(6):777-82. PubMed ID: 19926558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should Medicare adopt the Veterans Health Administration formulary?
    Frakt AB; Pizer SD; Feldman R
    Health Econ; 2012 May; 21(5):485-95. PubMed ID: 21506191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of national annual variation in total patient out-of-pocket Medicare Part D stand-alone prescription drug plan costs from 2007 to 2008.
    Walberg MP; Patel RA; Amaral MM
    J Med Econ; 2008; 11(4):625-37. PubMed ID: 19450072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Part D plan enrollment by uninsured medicare beneficiaries.
    Maciejewski ML; Farley JF; Hansen RA; Wei D; Harman JS
    Med Care; 2010 Feb; 48(2):183-6. PubMed ID: 20057332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.
    Cubanski J; Neuman P
    Health Aff (Millwood); 2007; 26(1):w1-12. PubMed ID: 17118944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceuticals and medical devices: Medicare Part D.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.
    Kennedy J; Dipzinski A; Roll J; Coyne J; Blodgett E
    Drug Alcohol Depend; 2011 Apr; 114(2-3):201-6. PubMed ID: 21134724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse selection in the Medicare prescription drug program.
    Riley GF; Levy JM; Montgomery MA
    Health Aff (Millwood); 2009; 28(6):1826-37. PubMed ID: 19887424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
    Jackson EA; Axelsen KJ
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug plan design incentives among Medicare prescription drug plans.
    Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
    Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Price stability. No hike expected in Medicare drug plan averages.
    Zigmond J
    Mod Healthc; 2011 Aug; 41(32):11. PubMed ID: 21879693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.